REG - Hikma Pharmaceutical - Director Declaration <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

28/01/2015 02:27

RNS Number : 0008D
Hikma Pharmaceuticals Plc
23 January 2015
Dr. Pamela Kirby Appointment to Reckitt Benckiser Group plc
London, 23 January 2015 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) makes this announcement in accordance with Listing Rule LR 9.6.14, which requires Hikma to notify the market when directors of Hikma become directors of other publicly traded companies.
Dr. Pamela Kirby, an independent non-executive director of Hikma, has been appointed as an independent non-executive director of Reckitt Benckiser Group plc (LSE: RB) with effect from 10 February 2015.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary  +44 (0)20 7399 2760
Notes to Editors
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDNBJMBTMBITBTA